| Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
| Germline and somatic genetic landscape of pediatric myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Understanding infectious complications in patients with lower risk myelodysplastic syndromes: a step towards improving survival |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Pathogenesis of paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Advances and challenges in the treatment of myelodysplastic syndromes |
|
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy |
|
Blood Advances |
Aplastic Anemia |
| What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria? |
|
Annals of Hematology |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
